548 related articles for article (PubMed ID: 31859415)
1. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
[TBL] [Abstract][Full Text] [Related]
2. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
[TBL] [Abstract][Full Text] [Related]
3. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel.
Escuriola-Ettingshausen C; Auerswald G; Königs C; Kurnik K; Scholz U; Klamroth R; Oldenburg J
Haemophilia; 2021 May; 27(3):e305-e313. PubMed ID: 32937002
[TBL] [Abstract][Full Text] [Related]
5. Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Bowyer A; Gray E; Lowe A; Murphy P; Platton S; Riddell A; Chowdary P; Lester W; Jenkins PV
Haemophilia; 2022 May; 28(3):515-519. PubMed ID: 35279922
[TBL] [Abstract][Full Text] [Related]
6. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.
Yacoub OA; Duncan EM
Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739
[TBL] [Abstract][Full Text] [Related]
7. Measurement of antifactor VIII antibody titre in the presence of emicizumab; Use of chromogenic Bethesda assays.
Bowyer A; Kitchen S; Maclean R
Int J Lab Hematol; 2021 Aug; 43(4):O204-O206. PubMed ID: 33764652
[No Abstract] [Full Text] [Related]
8. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
[TBL] [Abstract][Full Text] [Related]
9. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
11. Emicizumab-kxwh: First Global Approval.
Scott LJ; Kim ES
Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
[TBL] [Abstract][Full Text] [Related]
12. Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey.
Krumb E; Fijnvandraat K; Makris M; Peyvandi F; Ryan A; Athanasopoulos A; Hermans C
Haemophilia; 2021 Sep; 27(5):736-743. PubMed ID: 34191397
[TBL] [Abstract][Full Text] [Related]
13. Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab.
Miller CH; Boylan B; Payne AB; Driggers J; Bean CJ
Int J Lab Hematol; 2021 Apr; 43(2):e84-e86. PubMed ID: 33174329
[No Abstract] [Full Text] [Related]
14. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
15. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Gray E; Kitchen S; Bowyer A; Chowdary P; Jenkins PV; Murphy P; Platton S; Riddell A; Lester W
Haemophilia; 2020 Jan; 26(1):6-16. PubMed ID: 31846168
[TBL] [Abstract][Full Text] [Related]
16. Emicizumab: A Review in Haemophilia A.
Blair HA
Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
[TBL] [Abstract][Full Text] [Related]
17. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia A: Emicizumab monitoring and impact on coagulation testing.
Nardi MA
Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
20. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
